Abstract
In the wake of the pandemic of coronavirus disease 2019 (COVID-19), contact tracing has become a key element of strategies to control the spread of severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2). Given the rapid and intense spread of SARS-CoV-2, digital contact tracing has emerged as a potential complementary tool to support containment and mitigation efforts. Early modelling studies highlighted the potential of digital contact tracing to break transmission chains, and Google and Apple subsequently developed the Exposure Notification (EN) framework, making it available to the vast majority of smartphones. A growing number of governments have launched or announced EN-based contact tracing apps, but their effectiveness remains unknown. Here, we report early findings of the digital contact tracing app deployment in Switzerland. We demonstrate proof-of-principle that digital contact tracing reaches exposed contacts, who then test positive for SARS-CoV-2. This indicates that digital contact tracing is an effective complementary tool for controlling the spread of SARS-CoV-2. Continued technical improvement and international compatibility can further increase the efficacy, particularly also across country borders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MS received funding from the European Union's Horizon 2020 research and innovation programme - project "Versatile emerging infectious disease observatory - forecasting, nowcasting and tracking in a changing world (VEO)" (No. 874735). CA received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (No 101003688) and the Swiss National Science Foundation (grant 196046). NL received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (No 101003688) and the Swiss National Science Foundation (grant 176233). TB, DM and VvW received funding from the Cantonal Health Directorate Zurich, the Federal Office of Public Health, the University of Zurich Foundation Pandemic Fund and the Fondation Les Murons for the Zurich SARS-CoV-2 Cohort. EPFL is receiving base funding for both research and development of SwissCovid from the Fondation Botnar.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Zurich Sars-CoV-2 Cohort Study has been approved by the Ethics Commission of the Canton of Zurich (BASEC Nr. 2020-01739). Written informed consent has been obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data to reproduce results will be available upon peer-reviewed publication.
